Business News Agency, January 10: In the first half of 2010, cough and phlegm drugs in cities of Guangzhou, Wuhan, and Chengdu increased 70% over the same period, and Chinese patent medicine accounted for 76.98%.
In the fall and winter season, climate change is large and the human immune system is reduced. Cough is more common in the population, and this is also the peak season for sales of cough and phlegm drugs.
Cough is a defensive reflex activity. The body excretes respiratory secretions and foreign substances that have been inhaled into the respiratory tract by coughing. Radon is an excessive secretion produced by bronchial mucinous glands and goblet cells when it is inflammatory in the respiratory tract, and it can stimulate coughing in the respiratory mucosa. In the selection of respiratory medicines, cough relieving and phlegm always supplement each other.
At the end of 2009, the world was affected by a stream of flu, which drove sales of flu drugs and related "rubbing edge" drugs. At the same time, the introduction of the new medical reforms and the state's essential medicine system has hit the retail market. Against this backdrop, what is the development trend of cough and phlegm drugs?
Market expansion of proprietary Chinese medicines
From the end of 2009 to the beginning of 2010, the south of China was hit by a stream of low-flowing and cold waves, and supply of anti-influenza drugs was in short supply. Having undergone the baptism of SARS and A stream, the people's health awareness and self-medication level have been improved, and the psychology of the people purchasing drugs has changed. The cough and phlegm-removing drugs that were not taken seriously in the past have been favored. According to the analysis of the China Drug Retail Monitoring and Analysis System of the SFDA Southern Medicine Economic Research Institute's Guangzhou Punctuation Medical Information Co., Ltd., in the first half of 2010, sales in the retail markets of cough and phlegm-removing drugs in three southern cities of Guangzhou, Wuhan, and Chengdu continued to increase. The first half of 2009 increased by 70% over the same period, and the market potential cannot be ignored.
In the first half of 2010, in the three cities mentioned above, the proportion of proprietary Chinese medicines for cough and phlegm-removal remained the largest, followed by chemical drugs (Figure 1). Chinese patent medicine accounted for 76.98%, an increase of 0.11 percentage points over the first half of 2009. Chemicals accounted for 11.97%, a decrease of 1.63 percentage points from the same period of last year. The combination of Chinese and Western medicines increased by 1.53 percentage points over the same period of last year.
The competition is fierce
As shown in Table 1, in the first half of 2010, the top five brands in the retail market for cough and phlegm-removing drugs were Nicole Pills, Chuanbei Pills, Kechuanshun Pills, Huifening Solutions, Acute Bran Syrup, and Shedan Chuanbei. Cream. The total market share of the top five brands (CR5) does not exceed 30%, market concentration falls, and brand competition is fierce.
The market share of No.1 Ninth Ci Qin Chuan Bei Bei Gao in the first half of 2010 was 15.53%, a decrease of 5.77 percentage points from the same period of last year, but total retail sales increased by nearly 30% from the same period of last year. Although the market share has been squeezed, its status as a gimmick is difficult to shake.
Among the top five brands, only Huifening is a western medicine, and the rest are proprietary Chinese medicines. The first and the fifth place are all ointment. The total market share is close to 20%, ahead of other brands. It can be seen that traditional Chinese patent medicines, especially ointments, have a long history, no addiction, good taste, and are widely recognized by the people for cough and phlegm.
Antitussive and phlegm preparations include ointments, oral liquids, tablets, capsules, granules and pills. In view of timeliness and safety, the people are still taking traditional dosage forms as their main drug choice. In the three cities in the first half of 2010, retail sales data (Figure 2) showed that oral liquids and ointments accounted for the largest proportion, followed by tablets and thirdly for capsules, which accounted for 59.25%, 13.75%, and 10.01%, respectively.
In the three cities, there are more than 300 manufacturers producing oral liquids and ointments for cough and phlegm. The top four producers of cough and phlegm-like oral liquids and ointments are: Nicaragua General Plant in Kyoto, Hong Kong, Pangashou Pharmaceutical, Tai Chi Group, and Wyeth Pharmaceutical. The total market share (CR4) is 45.80%. The market is relatively mature and competition is still fierce.
It is worth mentioning that Nicole, Pan Gaoshou and Taiji Group are the top three in terms of local advantage. The No. 1 ranking of the Nintendo Plant of Kyoto is only a brand of Nindy Peach Honey. Its advertising phrase “Nian Ci 庵 庵 庵 点 æ…ˆ 慈†is deeply rooted in the hearts of the people, relying on its popularity and good quality, taking the cultural tradition and emotional marketing front, and occupying nearly 30% of oral liquids and ointments. The second-ranking Pangaoshou Pharmaceuticals is more focused on product penetration and complete coverage on dosage forms. The four types of decoctions, oral liquids, and syrups from the "Fighting Ipomoea Chuanbei Decoction", "Shedan Chuanbei Decoction", "Michelin Chuanbei Decoction", and "Shedan Chuanbei Decoction" have been further expanded to The new dosage form fully meets the different needs of the masses and creates a new conceptual orientation for the “cough suppressant expertâ€. What kind of marketing strategy is more popular among the people and remains to be seen.
Pediatrics and children's medication for a hundred schools of thought
In the first half of 2010, the top five brands in the retail market for cough and phlegm drugs in children and children were Xiaoerfeike Kechuan Oral Liquid, Xiaoer Xiaoji Zhike Oral Liquid, Huifeining Solution (children), and Pediatric Kechuanling Granules. Qingfeihuayu granules for children, the market share of 10.20%, 9.53%, 9.27%, 5.01% and 4.31%. Market share is not far behind, presenting a hundred schools of thought. The five brands focus on their respective characteristics and gradually subdivide the market for children and children.
The No. 1 sunflower brand Xiaofeifeike Kechuan Oral Liquid, which contains anti-viral Chinese medicine ingredients, was certified by the Heilongjiang Provincial Department of Health in 2009 as the nation's first child-prepared drug for the prevention and treatment of influenza A H1N1 influenza. In 2010, the Department of Health issued the “H1N1 Influenza Diagnosis and Treatment Plan (2010 Version)â€, and included the children's Feire Kechuan Granules (oral liquid) and Xiaoer Kechuanling Granules (oral liquid) in the newly established children's drug program. . Affected by the flow of A, its market demand has rapidly expanded and sales have increased significantly. In the first half of 2010, the market share of Xiaoerfeike Kechuan Oral Liquid in children's and children's cough and phlegm-removing drugs increased by 1.55% year-on-year, and retail sales more than doubled from the same period of last year.
In the fall and winter season, climate change is large and the human immune system is reduced. Cough is more common in the population, and this is also the peak season for sales of cough and phlegm drugs.
Cough is a defensive reflex activity. The body excretes respiratory secretions and foreign substances that have been inhaled into the respiratory tract by coughing. Radon is an excessive secretion produced by bronchial mucinous glands and goblet cells when it is inflammatory in the respiratory tract, and it can stimulate coughing in the respiratory mucosa. In the selection of respiratory medicines, cough relieving and phlegm always supplement each other.
At the end of 2009, the world was affected by a stream of flu, which drove sales of flu drugs and related "rubbing edge" drugs. At the same time, the introduction of the new medical reforms and the state's essential medicine system has hit the retail market. Against this backdrop, what is the development trend of cough and phlegm drugs?
Market expansion of proprietary Chinese medicines
From the end of 2009 to the beginning of 2010, the south of China was hit by a stream of low-flowing and cold waves, and supply of anti-influenza drugs was in short supply. Having undergone the baptism of SARS and A stream, the people's health awareness and self-medication level have been improved, and the psychology of the people purchasing drugs has changed. The cough and phlegm-removing drugs that were not taken seriously in the past have been favored. According to the analysis of the China Drug Retail Monitoring and Analysis System of the SFDA Southern Medicine Economic Research Institute's Guangzhou Punctuation Medical Information Co., Ltd., in the first half of 2010, sales in the retail markets of cough and phlegm-removing drugs in three southern cities of Guangzhou, Wuhan, and Chengdu continued to increase. The first half of 2009 increased by 70% over the same period, and the market potential cannot be ignored.
In the first half of 2010, in the three cities mentioned above, the proportion of proprietary Chinese medicines for cough and phlegm-removal remained the largest, followed by chemical drugs (Figure 1). Chinese patent medicine accounted for 76.98%, an increase of 0.11 percentage points over the first half of 2009. Chemicals accounted for 11.97%, a decrease of 1.63 percentage points from the same period of last year. The combination of Chinese and Western medicines increased by 1.53 percentage points over the same period of last year.
The competition is fierce
As shown in Table 1, in the first half of 2010, the top five brands in the retail market for cough and phlegm-removing drugs were Nicole Pills, Chuanbei Pills, Kechuanshun Pills, Huifening Solutions, Acute Bran Syrup, and Shedan Chuanbei. Cream. The total market share of the top five brands (CR5) does not exceed 30%, market concentration falls, and brand competition is fierce.
The market share of No.1 Ninth Ci Qin Chuan Bei Bei Gao in the first half of 2010 was 15.53%, a decrease of 5.77 percentage points from the same period of last year, but total retail sales increased by nearly 30% from the same period of last year. Although the market share has been squeezed, its status as a gimmick is difficult to shake.
Among the top five brands, only Huifening is a western medicine, and the rest are proprietary Chinese medicines. The first and the fifth place are all ointment. The total market share is close to 20%, ahead of other brands. It can be seen that traditional Chinese patent medicines, especially ointments, have a long history, no addiction, good taste, and are widely recognized by the people for cough and phlegm.
Antitussive and phlegm preparations include ointments, oral liquids, tablets, capsules, granules and pills. In view of timeliness and safety, the people are still taking traditional dosage forms as their main drug choice. In the three cities in the first half of 2010, retail sales data (Figure 2) showed that oral liquids and ointments accounted for the largest proportion, followed by tablets and thirdly for capsules, which accounted for 59.25%, 13.75%, and 10.01%, respectively.
In the three cities, there are more than 300 manufacturers producing oral liquids and ointments for cough and phlegm. The top four producers of cough and phlegm-like oral liquids and ointments are: Nicaragua General Plant in Kyoto, Hong Kong, Pangashou Pharmaceutical, Tai Chi Group, and Wyeth Pharmaceutical. The total market share (CR4) is 45.80%. The market is relatively mature and competition is still fierce.
It is worth mentioning that Nicole, Pan Gaoshou and Taiji Group are the top three in terms of local advantage. The No. 1 ranking of the Nintendo Plant of Kyoto is only a brand of Nindy Peach Honey. Its advertising phrase “Nian Ci 庵 庵 庵 点 æ…ˆ 慈†is deeply rooted in the hearts of the people, relying on its popularity and good quality, taking the cultural tradition and emotional marketing front, and occupying nearly 30% of oral liquids and ointments. The second-ranking Pangaoshou Pharmaceuticals is more focused on product penetration and complete coverage on dosage forms. The four types of decoctions, oral liquids, and syrups from the "Fighting Ipomoea Chuanbei Decoction", "Shedan Chuanbei Decoction", "Michelin Chuanbei Decoction", and "Shedan Chuanbei Decoction" have been further expanded to The new dosage form fully meets the different needs of the masses and creates a new conceptual orientation for the “cough suppressant expertâ€. What kind of marketing strategy is more popular among the people and remains to be seen.
Pediatrics and children's medication for a hundred schools of thought
In the first half of 2010, the top five brands in the retail market for cough and phlegm drugs in children and children were Xiaoerfeike Kechuan Oral Liquid, Xiaoer Xiaoji Zhike Oral Liquid, Huifeining Solution (children), and Pediatric Kechuanling Granules. Qingfeihuayu granules for children, the market share of 10.20%, 9.53%, 9.27%, 5.01% and 4.31%. Market share is not far behind, presenting a hundred schools of thought. The five brands focus on their respective characteristics and gradually subdivide the market for children and children.
The No. 1 sunflower brand Xiaofeifeike Kechuan Oral Liquid, which contains anti-viral Chinese medicine ingredients, was certified by the Heilongjiang Provincial Department of Health in 2009 as the nation's first child-prepared drug for the prevention and treatment of influenza A H1N1 influenza. In 2010, the Department of Health issued the “H1N1 Influenza Diagnosis and Treatment Plan (2010 Version)â€, and included the children's Feire Kechuan Granules (oral liquid) and Xiaoer Kechuanling Granules (oral liquid) in the newly established children's drug program. . Affected by the flow of A, its market demand has rapidly expanded and sales have increased significantly. In the first half of 2010, the market share of Xiaoerfeike Kechuan Oral Liquid in children's and children's cough and phlegm-removing drugs increased by 1.55% year-on-year, and retail sales more than doubled from the same period of last year.
Real Time Pcr System,Real Time Pcr System Q320,Real Time Pcr Thermal Cycler
Jiangsu Dinai Bioengineering Co.,ltd. , https://www.dinaipcr.com